Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498298 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL2497399 | 0.76 | EGLN1 (0.42) | ALDH1A1POLB | |
| SCHEMBL2493824 | 0.75 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL2498218 | 0.75 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL2500260 | 0.72 | LMNA (0.45) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL15359266 | 0.70 | MAPT (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL2497674 | 0.70 | ALDH1A1 (0.61) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL17886231 | 0.69 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL20568601 | 0.68 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL1401174 | 0.68 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2150251-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | Amgen, Inc (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | EGLN3, HIF1AN, EGLN2 | ALDH1A1 108/4885KDM4E 873/4885SMN1; SMN2 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.